JAMA NetworkAssessment of 25-Year Survival of Women with ER+/ERBB2- Breast Cancer Treated w. and without Tamoxifen Therapy

This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated in the Stockholm tamoxifen (STO-3) trial from 1976 to 1990.